Myelomeningocele in a child with intrauterine exposure to efavirenz.
about
An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patientsEfavirenz and the CNS: what we already know and questions that need to be answeredAssociation between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11)Implications of gender and pregnancy for antiretroviral drug dosingNeurological and psychiatric adverse effects of antiretroviral drugs.Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age.Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USAEffect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Myelomeningocele in an infant with intrauterine exposure to efavirenz.Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.First trimester exposure to antiretroviral therapy and risk of birth defectsPrevalence of congenital anomalies in infants with in utero exposure to antiretroviralsInitial antiretroviral therapy in chronically-infected HIV-positive adults.Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and EfavirenzEfavirenz for HIV-1 infection in adults: an overview.The safety of antiretroviral drugs in pregnancy.Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conceptionPrevention of mother-to-child transmission of HIV: treatment options.Current status of antiretroviral therapy.Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.Adherence to antiretrovirals among US women during and after pregnancy.Managing mother-to-child transmission of HIV infection in developed-country settings.Potential of polymeric nanoparticles in AIDS treatment and prevention.Pharmacokinetic optimization of antiretroviral therapy in pregnancy.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Has the time come to abandon efavirenz for first-line antiretroviral therapy?Clinical focus: infections in pregnancy.Polymeric anti-HIV therapeutics.British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review).Switching antiretroviral regimes for the treatment of HIV: safety implications.Encephalocele following a periconceptional exposure to efavirenz: a case report.British HIV Association guidelines for the management of HIV infection in pregnant women 2012
P2860
Q26827791-09FAF413-0259-41FE-853A-D40BD9D8CA37Q28085028-A7D4267D-3A5D-4E8D-9A91-3E495AE5B713Q28538279-213E0C50-3CA6-4E00-80F5-D15804CC61F2Q33584069-371A2E67-6E12-4F0F-8EA7-7B6DC983A278Q34039419-92C4EB18-25D4-40F8-BE33-F9B876366F08Q34170220-CF4F8C2C-C28F-4FA5-97F0-C836F68FDA7CQ34440361-4B5CAAFB-F01D-455D-B9E0-76552A390F36Q34440857-5CF450BF-727A-4C24-A933-6C21CA8CB30DQ34443184-A1E2287C-8264-4CC0-97AD-D4F50E735AB2Q34559568-59AB742E-3C3E-4BD5-B8CB-36B9E50628D1Q34609879-121988F2-151E-4A59-A44D-FBA707B2D802Q34638302-11B92C4F-93C4-472E-A290-694819B175C7Q35557216-6BAE109D-654E-4EFF-848A-E6635CD62396Q35572618-5D46C20E-EF0D-4203-B7A5-A125116D843DQ35680819-DB2D89A7-B61E-4C1D-8D05-100D3049B7E5Q35688173-D658D5B6-A269-4B66-AFAB-0E29099C74B1Q35784583-D7D06B20-EC78-44CD-A03C-8C31B6341053Q35821164-D9A3467C-45A2-47EC-8269-98EBC551DA76Q35917519-8BADABFA-75EB-4B89-906C-94F863371822Q36082030-BAB50D5F-46EC-4776-8B4C-3463C7999DF6Q36193392-34918CCE-AD5D-425F-BE7F-EA0F5374D8FEQ36322136-4EA27E1E-309C-409A-AC39-7D2DD100E7CEQ36548703-EDF56ACB-E567-4CFD-A17D-E7F9F083DD5DQ37045192-36D81EAF-5AB2-4FA2-9C0D-FC2A5E531D86Q37326983-EEA8C614-792A-4C93-AA05-446929549266Q37393613-DE35509C-1E65-428A-B129-60F322B637B7Q37608356-7123A900-9162-4F2A-A01C-4718C47A568BQ37818325-EA48D5FE-C22D-48F1-85A0-1E8855E6D244Q38047214-C3C77607-0484-4646-BE95-BD7BFC8EDAB0Q38051400-44B6BA1E-F995-4653-A43A-FBBB6DFE3D2FQ38194051-2F426820-35EF-46CA-B3D1-455FF1DBA578Q38207464-3411030E-CCBA-4E4B-8203-B31DEA1D4762Q38245819-E357E16E-B226-4F27-9B44-9245779D9807Q38325427-C3829562-E2D5-4A77-AB7C-13E1326ACFFAQ38879406-5005D30A-9B95-42F9-8D3A-7533D9B8C2FFQ42239227-B4AADE51-AF69-4A85-9C03-A737A1154417Q57076282-E04E8C4B-70A0-4F96-A935-B1500CCD5F96
P2860
Myelomeningocele in a child with intrauterine exposure to efavirenz.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Myelomeningocele in a child with intrauterine exposure to efavirenz.
@en
Myelomeningocele in a child with intrauterine exposure to efavirenz.
@nl
type
label
Myelomeningocele in a child with intrauterine exposure to efavirenz.
@en
Myelomeningocele in a child with intrauterine exposure to efavirenz.
@nl
prefLabel
Myelomeningocele in a child with intrauterine exposure to efavirenz.
@en
Myelomeningocele in a child with intrauterine exposure to efavirenz.
@nl
P2093
P1433
P1476
Myelomeningocele in a child with intrauterine exposure to efavirenz
@en
P2093
Carlo Fundarò
Claudia Rendeli
Elio Salvaggio
P304
P356
10.1097/00002030-200201250-00025
P407
P577
2002-01-01T00:00:00Z